A LESSON IN STATISTICS
Maximizing returns on proof of concept oncology trials
SAN DIEGO – When designing phase II proof of concept trials, companies want to maximize the chance of seeing a signal. Avoiding so-called type III errors – trials that would have been successful but were never performed – leads to a "no drug left behind" mentality, Cong Chen, director of biostatistics and research decision science at Merck & Co. Inc. told the audience during a panel at the American Association for Cancer Research meeting last week.
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.